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Purpose: To confirm the efficacy and safety of rimonabant, the first selective CB1 
receptor blocker, for improving cardiometabolic risk (CMR) factors in a pooled RIO 
trials population. 
Methods: Pooled data from the RIO-Europe, RIO-North America and RIO-Lipids 
trials, which included non-diabetic overweight/obese patients with/without 
comorbidities, 
and data from RIO-Diabetes, a trial including overweight/obese patients 
with type 2 diabetes, were analysed. Patients (on a mild hypocaloric diet) were 
randomised to placebo, or rimonabant 5 or 20 mg/day. 
Results: Changes in CMR factors over 1 year for placebo and rimonabant 20 
mg/day (RIM 20) are shown for both populations (table); for specific CMR factors 
approximately 50% of improvements were beyond the effect of weight loss alone. 
In all RIO studies, rimonabant had a favourable safety profile. 
 Conclusion: Rimonabant 20 mg/day significantly improved multiple CMR factors 
in diabetic as well as non-diabetic overweight/obese patients, and was generally 
well tolerated. 
 
